Vanucizumab reduces vessel permeability, perfusion and cellular density of tumor lesions in cancer patients as measured by DCE-MRI and DW-MRI

Date 26 September 2015
Event European Cancer Congress 2015
Session Early Drug Development I
Topics Drug Development
Presenter Nayak, N.